Therapy News and Research

RSS

Indian High Court forms committee to address HIV/AIDS in prisons

The high court in Mumbai, India, on Thursday formed a committee to create guidelines aimed at preventing the spread of HIV in prisons in response to the increasing spread of the virus among inmates, the Daily News & Analysis reports.

16 Sep 2008

Novel treatment for prostate cancer

Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.

15 Sep 2008

Trabectedin shows promise for ovarian cancer

Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.

15 Sep 2008

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

15 Sep 2008

Promising new treatment option for women with recurrent ovarian cancer

Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

15 Sep 2008

Vaccine against HER2-positive breast cancer offers complete protection in lab

Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity.

15 Sep 2008

Pathways to clinical goals speeds cancer therapy approval

Although cancer remains a leading cause of death in America, it can take up to 12 years to bring a new anti-cancer agent before the FDA and the success rate for approval is only five to 10 percent. That means many research hours and dollars are wasted chasing avenues that will not bring fruit.

15 Sep 2008

Scientists identify kidney failure susceptibility gene

Scientists at Johns Hopkins schools of Public Health and Medicine have, for the first time, identified variants in the gene MYH9 that are associated with increased risk for non-diabetic end stage renal disease (ESRD,) which is the near-loss of kidney function leading to either dialysis of transplant. MYH9, located on the 22 chromosome, is the first gene identified for common forms of kidney disease.

15 Sep 2008

Investigational drug shows promise in ovarian cancer

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

15 Sep 2008

Gender differences in experience of rheumatism

Rheumatoid arthritis is often a more painful experience for women than it is for men, even though the visible symptoms are the same.

15 Sep 2008

Keppra XR approved in the U.S. for partial onset seizures

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra XR (levetiracetam extended-release tablets) for use as an add-on to other antiepileptic treatments for people with partial onset seizures who are 16 years of age and older. Keppra XR is expected to be available in U.S. pharmacies at the end of September 2008.

15 Sep 2008

One million pounds to improve access to physiotherapy

Providing timely access to physiotherapy is a long-standing problem for the NHS, with more than 4 million new referrals each year and waiting times of several months in many areas. A Bristol-led study to improve access has been given £1.06 million by the Medical Research Council (MRC).

15 Sep 2008

Scientists develop nanometer-sized 'cargo ships' to target and destroy tumors

Scientists have developed nanometer-sized 'cargo ships' that can sail throughout the body via the bloodstream without immediate detection from the body's immune radar system and ferry their cargo of anti-cancer drugs and markers into tumors that might otherwise go untreated or undetected.

11 Sep 2008

Bad teeth, bleeding gums and poor dental hygiene can lead to heart disease

Scientists are warning that bad teeth, bleeding gums and poor dental hygiene can lead to heart disease.

11 Sep 2008

Radiation treatment less likely for African American women fighting breast cancer

According to a new study, African American women with breast cancer who have a lumpectomy are less likely to receive radiation treatment compared to white women-the standard for early stage breast cancer.

10 Sep 2008

Abuse of painkillers can predispose adolescents to lifelong addiction

No child aspires to a lifetime of addiction. But their brains might. In new research to appear online in the journal Neuropsychopharmacology today, Rockefeller University researchers reveal that adolescent brains exposed to the painkiller OxyContin can sustain lifelong and permanent changes in their reward system - changes that increase the drug's euphoric properties and make such adolescents more vulnerable to the drug's effects later in adulthood.

10 Sep 2008

Bleeding gums increase risk of heart disease

Bad teeth, bleeding gums and poor dental hygiene can cause heart disease, Professor Howard Jenkinson from the University of Bristol will tell members of the Society for General Microbiology in Trinity College, Dublin today [Thursday 11 September].

10 Sep 2008

New drug hope for cystic fibrosis patients

A science conference in the UK has heard some good news which offers hope to cystic fibrosis (CF) patients worldwide.

10 Sep 2008

ThermoGenesis announces distribution agreement for bone marrow stem cell device

ThermoGenesis Corp. announced today it has signed a distribution agreement with Celling Technologies for ThermoGenesis' MarrowXpress (MXP(TM)) product line used for isolating stem cells from bone marrow. The distribution rights are for the field of use in orthopedic intraoperative or point-of-care applications.

9 Sep 2008

New drug hope for cystic fibrosis patients

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol told an audience at the BA Festival of Science in Liverpool today [9 September].

9 Sep 2008